Marino Med

Marinomed Biotech AG is a biopharmaceutical company that focuses on developing innovative therapeutics and medical devices, particularly in the virology and immunology fields, addressing critical health challenges. Founded in 2006, Marinomed Biotech AG operates from Vienna, Austria, specializing in therapeutics for viral diseases and immune disorders. The company has engaged in at least one significant deal, with their most recent funding round occurring on March 21, 2016, where Invest AG invested in Marinomed without disclosing financial terms. The company's leadership includes a founder who is not explicitly named in available resources but has a background in the biotech sector.

Marinomed Biotech AG specializes in the development of therapeutics such as Budesolv, Tacrosolv, and Satiasolv, which target viral infectious diseases and autoimmune disorders. Their products are aimed at healthcare providers, hospitals, and pharmacies, primarily in European markets like Austria and Switzerland, with ongoing expansion plans into additional regions. In the fiscal year 2021, Marinomed reported a revenue of EUR 13,791,684. 50, with an EBITDA of EUR -5,617,951.

70, reflecting their financial performance during that period. The company's revenue growth is largely attributed to partnerships and collaborations with pharmaceutical firms that facilitate the marketing and distribution of their proprietary products. Marinomed plans to introduce new products aimed at addressing unmet medical needs in the virology and immunology sectors. They are targeting expansion into additional European markets and potentially beyond by 2025.

The funding secured from the 2016 investment round will support these growth initiatives, allowing for increased research and development activities and the establishment of new partnerships for broader market access.